Assessment of the p-glycoprotein expression by 99mtc-mibi bone marrow imaging in patients with untreated leukaemia

Nuclear Medicine Communications

Volumn 24, Issue 4, 2003, Pages 397-402

  AK, A ^a   Aslan, V ^a   VardarelI E ^a   GULBAS Z ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

99mTc MIBI; Leukaemia; P glycoprotein

Indexed keywords

DIAGNOSTIC AGENT; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL TRIAL; FEMALE; HUMAN; LEUKEMIA; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; TISSUE DISTRIBUTION; VALIDATION STUDY; WHOLE BODY COUNTING;

ADULT; AGED; BONE MARROW; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TECHNETIUM TC 99M SESTAMIBI; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 0346856108     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200304000-00009     Document Type: Article

References (27)

1. Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002; 57: 385-415.
2. Bradshaw D, Arceci R. Clinical relevance of transmembrane drug efflux as a multidrug resistance. J Clin Oncol 1998; 16: 3674-3690.
3. Sikic B. Pharmacologic approach to reversing multidrug resistance. Semin Hematol 1997; 94: 40-47.
4. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999; 17: 94-95.
5. Gottesman M, Fojo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002; 2: 48-58.
6. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med 2002; 43: 519-525.
7. Wackers F, Berman D, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301-311.
8. Chiu M, Kronauge J, Piwnika-Worms D. Effect of mitocondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium(I) in cultured mouse fibroblast. J Nucl Med 1990; 31: 1646-1653.
9. Delmon-Moingeon L, Piwnica-Worms D, Van den Abbeele A, Holman L, Davidson A, Jones A. Uptake of cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell line in vitro. Cancer Res 1990; 50: 2198-2202.
10. Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
11. Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, Croop J. Functional imaging of multidrug resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
12. 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. Eur J Nucl Med Mol Imaging 2002; 29: 809-814.
13. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumour clearance of technetium 99m-sestamibi as a predictor of responce to neoadjuvant chemoteraphy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
14. Cordobes M, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
15. Kostakoglu L, Ruacan S, Ergun E, Sayek I, Elahi N, Bekdik C. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med 1998; 39: 228-234.
16. Massart C, Gibassier J, Raoul M, et al. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anticancer Drugs 1995; 6: 135-146.
17. Webb M, Raphael C, Asbahr H, Erber W, Meyer B. The detection of rhodamine-123 efflux at low levels of drug resistance. Br J Haematol 1996; 93: 650-655.
18. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001; 42: 1476-1483.
19. Kostakoglu L, Kiratli P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998; 39: 228-234.
20. 99mTc-sestamibi SPET? Eur J Nucl Med 1998; 25: 401-409.
21. Kao A, Shiun S, Hsu N, Sun S, Lee C, Lin C. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 2001; 12: 1561-1566.
22. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001; 28: 1341-1350.
23. Tothova E, Elbertova A, Fricova ME, et al. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Neoplasma 2001; 48: 393-397.
24. Gruber A, Arestrom I, Xu D, Liliemark J, Larsson S, Jacobsson H. Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI. Br J Cancer 1998; 77: 1732-1725.
25. Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 1998; 39: 1191-1197.
26. Del Vecchio SD, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
27. Del Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997; 38: 1348-1351.